[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.191.72. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
July 2, 2003

Pain Management in Patients With Osteoarthritis—Reply

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;290(1):36. doi:10.1001/jama.290.1.36-a

To the Editor: In his Clinical Crossroads article about a 57-year-old man with arthritis, Dr Lonner1 stated that cyclooxygenase-2 (COX-2) selective inhibitors are as effective as nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), but may have "decreased toxicity on non-target tissues such as the gastric mucosa, although at 15 to 20 times the cost." In support of this assertion he cites data from the Celecoxib Long-term Arthritis Safety Study (CLASS).2 In fact, however, a later analysis revealed that 12 months of celecoxib was no safer than other NSAIDs, and the US Food and Drug Administration disagreed with the manufacturer's claim that celecoxib was safer.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×